Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

Apalutamide (CAS 956104-40-8)

0.0(0)
Write a reviewAsk a question

Datasheets
Alternate Names:
ARN-509; 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide
CAS Number:
956104-40-8
Molecular Weight:
477.40
Molecular Formula:
C21H15F4N5O2S
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

QUICK LINKS


Apalutamide (CAS 956104-40-8) References

  1. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.  |  Wang, SS., et al. 2024. Asian J Androl. 26: 402-408. PMID: 38624195
  2. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.  |  Hahn, AW., et al. 2024. BJU Int.. PMID: 38837608
  3. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.  |  El-Taji, O., et al. 2024. JAMA Oncol.. PMID: 38842801
  4. CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy.  |  Qi, Z., et al. 2024. J Transl Med. 22: 538. PMID: 38844946
  5. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies.  |  Daher, R., et al. 2024. Crit Rev Oncol Hematol. 200: 104420. PMID: 38906514
  6. Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report.  |  Hoshino, Y., et al. 2024. Int Cancer Conf J. 13: 250-255. PMID: 38962044
  7. Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.  |  Shore, N., et al. 2024. Prostate Cancer Prostatic Dis.. PMID: 38969791
  8. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.  |  Zhang, T., et al. 2024. Eur Urol Oncol.. PMID: 38971644
  9. Design, Characterization and Biopharmaceutical Applications of Novel Green Boron-Carbon Quantum Dots for Quantification of Apalutamide; Greenness Evaluations.  |  Hassan, YF., et al. 2024. J Fluoresc.. PMID: 38976089

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Apalutamide, 5 mg

sc-507442
5 mg
$290.00